FDA accepted Bayer kidney filing: Bayer stock gains 1.06 percent

Published on 10/16/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer's finerenone filing won FDA acceptance on October 8, 2026. Bayer stock costs EUR 44.88 on October 16, 2026, 1.06 percent above the Xetra close.

Regulatory and valuation markers

Finerenone reduced the cardiovascular-kidney risk by 23 percent in the FIND-CKD study on October 8, 2026.
JPMorgan retained its EUR 61.00 target and Overweight rating for Bayer on October 1, 2026.
Bayer stock trades at EUR 44.88 at 9:49 a.m. CEST at Lang & Schwarz on October 16, 2026, 1.06 percent above the Xetra close of October 15, 2026.

Extremmakroaufnahme einer weißen Tablette, in zwei Hälften gebrochen; die körnig-kristalline Bruchfläche ist scharf, dunkler Untergrund, dramatisches Seitenlicht von links — Extremmakro einer gebrochenen weißen Tablette: kristalline Bruchstruktur vor dunkelgrauem Hintergrund, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 44.88 at Lang & Schwarz on October 16, 2026 at 9:49 a.m. CEST, up 1.06 percent versus the Xetra close of October 15, 2026 at EUR 44.41. The latest company catalyst was the U.S. FDA's acceptance of Bayer's supplemental finerenone application for chronic kidney disease without diabetes on October 8, 2026, as Bayer reported.

Finerenone adds a measurable test

The filing is not an approval, but it gives Bayer a regulatory milestone in a large potential treatment area. In the Phase III FIND-CKD study, finerenone reduced the risk of the key cardiovascular-kidney outcome by 23 percent versus placebo and slowed the annual decline in estimated kidney function by 0.7 milliliters per minute per 1.73 square meters over 32 months, according to Bayer. The study included more than 1,500 patients, which gives the regulatory submission a defined clinical base.

Three dates frame the story

On June 30, 2026, Bayer's second-quarter report showed group sales growth of 2.20 percent, according to Bayer. On October 1, 2026, JPMorgan retained an Overweight rating and a EUR 61.00 price target, while warning that early third-quarter expectations might be too high because of timing in the agricultural business, reported FinanzNachrichten. On October 8, 2026, the FDA accepted the finerenone filing, with Bayer citing a 23 percent reduction in the key secondary outcome.

What will the November date test?

Bayer's next reporting checkpoint is November 3, 2026, when the company has scheduled its third-quarter results and quarterly statement, according to Bayer. The central question is whether the timing effects flagged by JPMorgan translate into a weaker quarter or leave full-year expectations broadly intact. That makes the upcoming report more important for the stock than the filing alone.

Results and regulatory progress

The next two scheduled events are November 3, 2026, for the Q3 results and November 3, 2026, for the investor video call. Bayer's market capitalization was EUR 44.2 billion as of October 16, 2026, while its 52-week range was EUR 25.78 to EUR 53.92. The current quote is therefore below the yearly high, but the 1.06 percent move above the Xetra close gives the October 8 filing a constructive short-term market backdrop.

Bayer was trading at EUR 44.88 at Lang & Schwarz on October 16, 2026 at 9:49 a.m. CEST, up 1.06 percent versus the Xetra close of October 15, 2026 at EUR 44.41. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.